Pokroy N, Ress S, Gregory M C
S Afr Med J. 1977 Nov 5;52(20):806-8.
A young male nephrotic patient, who was given small doses of clofibrate for hyperlipaemia, developed muscle pain, stiffness and very high serum levels of muscle enzymes. The myopathy remitted completely after administration of clofibrate was stopped. He also displayed a transient mononeuropathy and rapid deterioration of previously stable renal function, so that he required maintenance dialysis. Clofibrate has particular dangers in patients with uraemia or hypoproteinaemia, and we recommend that it be used with great caution in patients with renal disease.
